Cipla Limited (BSE: 500087) (NSE: CIPLA EQ), an India-based pharmaceutical company, announced on Thursday a significant expansion of its manufacturing facility located at Innovation Way in Fall River, Massachusetts.

This expansion includes an 83,000 sq ftaddition to the existing facility, aimed at increasing production capacity and enhancing operational efficiency. Cipla says that it is expanding its US manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, MA and Central Islip, Long Island NY.

According to Cipla, the expanded facility will feature state-of-the-art technology and advanced manufacturing processes. The facility is dedicated to the production of respiratory products for the US market, with comprehensive filling capabilities, quality assurance processes, and a specialised workforce trained in complex manufacturing.

Employing over 800 individuals in the US, Cipla has been selected as an awardee by Massachusetts Life Sciences Center (MLSC) in the latest round of the MLSC Tax Incentive Program and will receive tax incentive to support its expansion in Fall River, creating new jobs in the region. Cipla USA says that it is now actively hiring for various positions, including roles in manufacturing, quality control, engineering, and operations.